COMMON STOCK PURCHASE WARRANT BIOLABMART INC.Biolabmart Inc. • March 13th, 2017
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (as defined above) and on or prior to the close of business on December 31, 2019 (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioLabMart Inc., a Wyoming corporation (the “Company”), up to [ ] shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT QRONS INC.Qrons Inc. • June 21st, 2021 • Biological products, (no disgnostic substances) • Florida
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding of that certain convertible promissory note dated June 15, 2021, in the original principal amount of $115,000.00 issued by the Company (as defined below) to the Lender (as defined below) (the “Note”)), Quick Capital, LLC, a Wyoming limited liability company (the “Lender” and including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time during the Exercise Period, to purchase from Qrons Inc., a Wyoming corporation (the “Company”), up to 115,000 shares of Common Stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect. The number of Warrant Shares for which this Warrant may be exercised is subject to adjustment in accordance with the terms hereof. This Warrant is issued by the Company as of the Issuance Date pu
ContractBiolabmart Inc. • March 13th, 2017 • Florida
NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
NOTE PURCHASE AGREEMENTNote Purchase Agreement • June 21st, 2021 • Qrons Inc. • Biological products, (no disgnostic substances) • Florida
THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of June 15, 2021, (the “Execution Date”), is entered into by and between QRONS INC., a Wyoming corporation (the “Company”), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as otherwise defined herein.
LICENSE AND RESEARCH FUNDING AGREEMENTLicense and Research Funding Agreement • March 13th, 2017 • Biolabmart Inc.
This License Agreement is entered into as of this 14th day of December, 2016, by and between BioLabMart Inc., a company formed under the laws of the State of Wyoming, USA, having a place of business at 1900 Purdy Avenue, #1907, Miami Beach, Florida, 33139, (the “Company”) and Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University of Samaria (”AU”) having a place of business at Ariel University, Ariel, Israel 40700, (“Ariel”). Ariel and the Company shall each be referred to in this Agreement as a "Party" and together as the "Parties".
ROYALTY AND LICENSE FEE SHARING AGREEMENTRoyalty and License Fee Sharing Agreement • December 3rd, 2019 • Qrons Inc. • Biological products, (no disgnostic substances) • New York
This Royalty and License Fee Sharing Agreement (the “Agreement”) is entered into as of November 30, 2019 (the “Effective Date”), between Qrons Inc., a Wyoming corporation (the “Company”) and Ariel Scientific Innovations Ltd. (formerly known as Ariel R&D Co., Ltd.), a company organized under the laws of Israel ("Ariel", and together with the Company, the “Parties” and each a “Party” ).
License Agreement Term SheetLicense Agreement • July 24th, 2023 • Qrons Inc. • Biological products, (no disgnostic substances)
ADDENDUM #1 TO LICENSE AND RESEARCH FUNDING AGREEMENT dated Dec. 14th, 2016License and Research Funding Agreement • December 15th, 2017 • Qrons Inc. • Biological products, (no disgnostic substances)
Whereas, the Parties have entered into a Licenses and Research Funding Agreement (the "Agreement") dated as of December 14, 2016, and;
October 28, 2024 VIA EMAIL DELIVERY: Professor Benjamin Sredni Professor Michael Albeck Adv. Avichai Isachar Adv. Hananel Levy Re: License term Sheet Agreement effective July 17, 2023 ( the “Agreement”) Gentlemen: Pursuant to Paragraph 12 of the above...Qrons Inc. • November 8th, 2024 • Biological products, (no disgnostic substances)
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 30th, 2020 • Qrons Inc. • Biological products, (no disgnostic substances)
This securities purchase agreement (this “Agreement”) is made by and between Qrons Inc., a Wyoming corporation (the "Company"), and __________________, a citizen and resident of the State of _________________ (the “Undersigned”) as of December ___, 2019. The Undersigned hereby irrevocably agrees to purchase the Company’s eight percent (8%) convertible promissory note, issued in the amount of $_____________, the form of which is attached hereto as Exhibit A (the “Note”), which Note is and shall be, at the option of the Undersigned except as therein stated, convertible in accordance with its terms into shares of common stock of the Company, par value $0.0001 per share, which common stock trades on the OTC Markets “OTC-QB” under the symbol “QRON” ("Common Stock"). In addition to the Note, and as a material part of the Purchase Price (defined below), the Company shall issue to the Undersigned a warrant (the “Warrant”) to purchase _________ shares [one (1) share per dollar invested] of Comm
SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • July 18th, 2018 • Qrons Inc. • Biological products, (no disgnostic substances) • New Hampshire
This Sponsored Research Agreement ("Agreement") is made and is effective as of 07/12/2018 ("Effective Date") by and between Trustees of Dartmouth College, a non-profit, private educational and research institution under the laws of the State of New Hampshire ("Dartmouth") and Qrons Inc., a publicly traded, preclinical biotechnology company with a principal place of business at 777 Brickell Avenue, Suite 500, Miami, FL 33131 ("Sponsor").
SERVICES AGREEMENTServices Agreement • December 15th, 2017 • Qrons Inc. • Biological products, (no disgnostic substances)
This Services Agreement is entered into as of this 14th day of December, 2017 (the "Effective Date"), by and between Ariel Scientific Innovations Ltd., a company organized under the laws of Israel with offices at Ariel University ("AU"), Ariel, Israel ("Ariel") and Qrons Inc (formerly BioLabMart Inc), a company formed under the laws of the State of Wyoming, USA, having a place of business at 1900 Purdy Avenue, #1907, Miami Beach, Florida, 33139, (the "Company").
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • October 8th, 2019 • Qrons Inc. • Biological products, (no disgnostic substances) • New Hampshire
This License Agreement (this “Agreement”) is made by and between Qrons Inc., a Wyoming corporation with an address at 50 Battery Pl, #7T, New York, NY 10280 (“Licensee”) and Trustees of Dartmouth College (“Dartmouth”) with an address at 11 Rope Ferry Road, Hanover, NH 03755. This Agreement is effective as of September 3, 2019 (the “Effective Date”).
SUBSCRIPTION AGREEMENTSubscription Agreement • March 13th, 2017 • Biolabmart Inc. • New York
FIRST AMENDMENT TO SERVICES AGREEMENTServices Agreement • April 16th, 2019 • Qrons Inc. • Biological products, (no disgnostic substances)
First Amendment to the Services Agreement entered into on March 6, 2018, between Ariel Scientific Innovations Ltd., a company organized under the laws of Israel ("Ariel"), and Qrons Inc., a Wyoming corporation (the "Company").
THIRD AMENDMENT TO SERVICES AGREEMENTServices Agreement • March 30th, 2020 • Qrons Inc. • Biological products, (no disgnostic substances)
This Third Amendment to the Services Agreement, dated December 8, 2019, to the Services Agreement, dated December 14, 2017 between Ariel Scientific Innovations Ltd., a company organized under the laws of Israel ("Ariel"), and Qrons Inc., a Wyoming corporation (the “Company”). as amended by First Amendment to Services Agreement, dated April 12, 2018 and a Second Amendment to Services Agreement dated Dec. 14, 2018 (collectively, the “Services Agreement”)
ContractAdvisory Board Member Consulting Agreement • March 2nd, 2018 • Qrons Inc. • Biological products, (no disgnostic substances) • Florida
Leter of understanding between Qrons Inc. and Quick Capital, LLCQrons Inc. • August 14th, 2023 • Biological products, (no disgnostic substances)
By this leter agreement “Agreement” dated as of June 15, 2023, between Qrons Inc. Inc (the “Company”) and Quick Capital, LLC (the “Investor”) the parties agree as follows:
SERVICES AGREEMENTServices Agreement • August 12th, 2019 • Qrons Inc. • Biological products, (no disgnostic substances) • New York
This Agreement (this "Agreement") is made and entered into on August 8th, 2019, by and between PCG Advisory, Inc., a New York corporation, located at 150 East 58th Street, 20th Floor, New York, NY 10155 (the "Consultant") and Qrons Inc. (the "Client"), located at 50 Battery Pl, #7T, New York, NY 10280.
October 28, 2024 VIA EMAIL DELIVERY: Mr. Adiv Baruch, Chairman Mr. Danny Hardon, CEO Ariel Scientific Innovations Ltd. Ariel University Ariel 40070 Israel Re: Royalty and License Fee Sharing Agreement dated as of November 30, 2019 ( the “Agreement”)...Qrons Inc. • November 8th, 2024 • Biological products, (no disgnostic substances)
An Exit Event as defined by the above caption Agreement has occurred whereby Qrons has agreed to enter into a merger agreement. Pursuant to Paragraph 2, Qrons is issuing to Ariel University 3% of its issued and outstanding shares. Qrons currently has 13,949,789 such shares and will issue to Ariel 418,494 shares to be deposited into Ariel’s account at the Company’s Transfer Agent.
SECOND AMENDMENT TO SERVICES AGREEMENTServices Agreement • December 14th, 2018 • Qrons Inc. • Biological products, (no disgnostic substances)
Second Amendment to the Services Agreement, entered into on December 14, 2017, as amended by First Amendment to Services Agreement, dated April 12, 2018 (collectively, the "Services Agreement") between Ariel Scientific Innovations Ltd., a company organized under the laws of Israel ("Ariel"), and Qrons Inc., a Wyoming corporation (the "Company").
SERVICES AGREEMENTServices Agreement • April 16th, 2019 • Qrons Inc. • Biological products, (no disgnostic substances)
This Services Agreement (the "Agreement") is entered into as of this 6th day of March 2018 (the "Effective Date"), by and between Ariel Scientific Innovations Ltd (formerly known as Ariel R&D), a company organized under the laws of Israel with offices at Ariel University ("AU"), Ariel, Israel ("Ariel") and Qrons Inc. (formerly known as BioLabMart Inc.), a company formed under the laws of the State of Wyoming, USA, having a place of business at 1900 Purdy Avenue, #1907, Miami Beach, Florida, 33139, (the "Company").
FIRST AMENDMENT TOFirst Amendment Agreement • November 6th, 2019 • Qrons Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT AGREEMENT (“Amendment”), effective as of July 15, 2019, by and between the Trustees of Dartmouth College, a non-profit, private educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and Qrons Inc., a Wyoming corporation with a principal place of business at 50 Battery Place, #7T, New York, New York 10280 (hereinafter “Sponsor”).
OPTION AGREEMENTOption Agreement • October 20th, 2017 • Qrons Inc. • Biological products, (no disgnostic substances) • New Hampshire
THIS OPTION AGREEMENT ("Agreement") dated as of September 27, 2017 ("Effective Date") is entered into by Trustees of Dartmouth College, hereinafter referred to as "Dartmouth", a non-profit educational and research institution with an address at 11 Rope Ferry Road, Hanover, NH 03755, and Qrons Inc. a Wyoming corporation with its principal address at 777 Brickell Avenue, Suite 500, Miami, Florida 33139 (hereinafter referred to as "Company"), the signatories to this Agreement collectively referred to as the "Parties" and individually as a "Party" hereto.
QRONS INC. SUBSCRIPTION AGREEMENTSubscription Agreement • February 12th, 2018 • Qrons Inc. • Biological products, (no disgnostic substances) • New York
FIRST AMENDMENT AGREEMENT FOR SERVICES AGREEMENT BETWEEN QRONS AND ASIFirst Amendment Agreement • April 16th, 2018 • Qrons Inc. • Biological products, (no disgnostic substances)
This first amendment agreement (this "Amendment Agreement") is entered into as of April 12, 2018 (the "Amendment Effective Date"), by and between Qrons Inc., a company formed under the laws of Wyoming, USA, having a place of business at 1900 Purdy Avenue, #1907, Miami Beach, Florida ("Company") and Ariel Scientific Innovations, Ltd. ("ASI"), a company formed under the laws of the State Israel, having a place of business at Ariel University, Ariel. Company and ASI shall be referred to together in this Amendment Agreement as "the Parties".
Qrons And Dartmouth College Enter into One Year Sponsored Research AgreementQrons Inc. • July 18th, 2018 • Biological products, (no disgnostic substances)
Sponsored Research Agreement will allow for continued research in developing innovative 3D printable, bio compatible advanced materials and stem cell delivery techniques for Qrons' traumatic brain injury treatment. Qrons will also have the option to negotiate exclusive licenses.
ContractQrons Inc. • March 2nd, 2018 • Biological products, (no disgnostic substances) • Florida
NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
Letter of understanding between QRONS, Inc and Quick Capital, LLCLetter Agreement • March 31st, 2023 • Qrons Inc. • Biological products, (no disgnostic substances)
By this letter agreement “Agreement” dated December 7, 2022, between QRONS, Inc (the “Company”) and Quick Capital, LLC (the “Investor”) the parties agree as follows:
ADVISORY BOARD MEMBER CONSULTING AGREEMENTAdvisory Board Member Consulting Agreement • February 12th, 2018 • Qrons Inc. • Biological products, (no disgnostic substances) • New York
THIS ADVISORY BOARD MEMBER CONSULTING AGREEMENT ("Agreement") is made as of January 23, 2018, by and between Qrons Inc., a Wyoming corporation having an address at 777 Brickell Avenue, Suite 500, Miami, Florida, 33131 (the "Company"), and Pavel Hilman an individual with an address at ___________________________ (the "Advisor"). The Company and the Advisor may be referred to herein individually as "Party" or collectively, as "Parties."
